Entasis Therapeutics has made it to Nasdaq.
The antibiotics group — a spinout from AstraZeneca — had a disappointing debut, pricing shares at $15 apiece, below the range set between $16 to $18. But the biotech was able to raise $75 million after upsizing the number of shares on offer to 5 million.
The Waltham, MA-based company is run by a group of survivors from an antibiotics division that once employed 175 people working for AstraZeneca. The pharma giant bowed out of early-stage antibiotics research, as others have as well, and was unable to sell the unit, as it had originally hoped. In the spinout, the pharma giant also provided a launch round to fund the work.
That lack of enthusiasm for the work may help explain Entasis’ trouble with its IPO, which initially pencilled in a target of $86 million.
Credit Suisse and BMO Capital Markets were joint book runners.
The biotech will trade as $ETTX, joining a big wave of newly public biotechs which were pitched to investors this year.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.Free Subscription